A Global Challenge
Pandemic events, such as the one we are experiencing, will continue to happen. The existing, traditional approach to deciding on the fundamental immune instructions of a vaccine, called the vaccine antigen, does not anticipate how viruses mutate and evolve. The traditional approach of simply copying a circulating virus genetic sequence or protein to produce a vaccine antigen, is a limited, short-term strategy in terms of depth and breadth of protection. This traditional approach allows for imminent vaccine escape when a new strain arises, making it impossible to proactively vaccinate against future pandemic threats.
The missing piece
in the vaccine revolution
To break the old paradigm, we design VAPs (Vaccine Antigen Payloads, the immune instructions of a vaccine) from multiple synthetic, novel antigens. Our VAPs are custom designed to achieve the depth and breadth required to upend both the seasonal vaccine cycle, and usher in a new era of proactive, pandemic readiness. Our VAPs can be deployed in almost any form of vaccine vector such as nucleic acid-based platforms (i.e. DNA or mRNA vector vaccines), virus vectored vaccines (e.g. adenovirus or VSV) or protein based platforms.
Unique databases anticipating mutations and crossover events before they occur
Breadth & depth of protection to cover multiple strains and families of viruses
Vector agnostic platform with VAPs ready to plug into the best vaccine vector for the job
Our unique platform analyses the structure and evolution of viruses to achieve broad (cross family) and deep (mutation countering) protection. Computational modelling is used to graft epitope-rich regions from key immune targets into a single antigen structure, and in vivo and in vitro experiments verify each candidate's stability and breadth of efficacy.
Vectors act like a box, containing a VAP ready for delivery to the human body. Once administered, VAPs instruct the immune system on what protective immune responses to make. Different vectors are more suited to different types of viruses. The flexibility to deploy our VAPs in almost any vector enables DIOSynVax to tackle a wide spectrum of viral threats.
How it works
Our data reservoir is constantly growing with every iteration, employing machine learning to better identify how key areas of the virus are likely to change and how to generate vaccine candidates that will be protective long into the future. This system only gets smarter with time and experience.